April 29 (Reuters) -

Annovis Bio ( ANVS ) said on Monday its Alzheimer's

treatment showed significantly higher improvement in cognition

in patients during a mid-stage trial.

The company's drug buntanetap works by decreasing the

production of amyloid beta protein, believed to be a hallmark of

Alzheimer's, from the brain.

Annovis plans to conduct a late-stage trial based on

results of this trial.